Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9912 |
Trastuzumab
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Trastuzumab 是人源化单克隆抗体,以高亲和力与HER2选择性结合,可用于 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌的研究。 | |||
T36646 |
Trastuzumab deruxtecan
DS-8201a,VRN-101099,DS 8201,T-DXd |
Others | Others |
Trastuzumab deruxtecan (T-DXd) 是一种具有抗癌抗肿瘤活性的抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 对 HER2 阳性乳腺癌和胃癌有改善作用。 | |||
T80955 |
Trastuzumab duocarmazine
(vic)-Trastuzumab duocarmazine |
||
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) 是一款HER2靶向ADC,它通过组织蛋白酶B的识别和裂解作用,选择性地作用于肿瘤细胞。此化合物在子宫和卵巢癌肉瘤等癌症的研究中显示出抗肿瘤活性。 | |||
T36647 | Trastuzumab emtansine | Others | Others |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine. This compound is utilized in the investigation of advanced breast cancer[1][2]. | |||
T76971 | Trastuzumab beta | ||
Trastuzumab beta (ABP 980)是Trastuzumab的生物仿制药,靶向人表皮生长因子受体2 (HER2) 的单克隆抗体 (McAb)。该药物适用于研究HER2阳性转移性乳腺癌、早期乳腺癌 (EBC) 和转移性胃癌。 | |||
T38889 |
Thailanstatin A
|
||
Thailanstatin A 是真核 RNA 剪接抑制剂,IC50为650 nM,通过非共价结合到剪接体的 U2 snRNA 亚复合物的 SF3b 亚单位发挥作用。Thailanstatin A 对多种癌细胞系的抑制显示 nM 级别的 IC50。它与 Trastuzumab 上的赖氨酸结合,可产生“无连接子” ADC。 | |||
T9996 |
NCT-58
NCT58 |
HSP | Cytoskeletal Signaling; Metabolism |
NCT-58是一种有效的C 端HSP90抑制剂。NCT-58不会引起热休克反应(HSR)。NCT-58通过同时下调HER 家族成员以及抑制Akt 磷酸化来激发抗肿瘤活性。NCT-58杀死对曲妥珠单抗耐药的乳腺癌干细胞样细胞。NCT-58诱导HER2阳性乳腺癌细胞凋亡。 | |||
T36669 |
IYPTNGYTR acetate
|
||
IYPTNGYTR acetate, a deamidation-sensitive peptide derived from Trastuzumab, is a suitable tool for monitoring the metabolism of Trastuzumab in vivo [1]. | |||
T38906 |
IYPTNGYTR
|
||
IYPTNGYTR, a deamidation-sensitive peptide, is a deamidation derivative of Trastuzumab. This compound, IYPTNGYTR, can be utilized for monitoring Trastuzumab metabolism in vivo. | |||
T81288 | Rezetecán | ||
Rezetecán 是 Trastuzumab rezetecan 合成的原料,后者为抗肿瘤药物。 | |||
T74940 | Anticancer agent 81 | Apoptosis | Apoptosis |
Anticanceragent 81(Compound 37b3)是用于诱导肿瘤细胞发生周期阻滞和凋亡(apoptosis)的化合物。当Anticanceragent 81作为有效载荷与Trastuzumab结合时,可生成抗体药物偶联物(ADC)T-PBA,此ADC保留了Trastuzumab的靶向特性和内化功能。 | |||
T11936 |
Macropa-NCS
|
Others | Others |
Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. | |||
T81084 |
STING agonist-18
|
||
STINGagonist-18(compound 1a)适用于ADCs的合成,例如与Trastuzumab偶联。 | |||
T38023 |
FTISADTSK acetate
|
||
FTISADTSK acetate is a stable endogenous signature peptide sourced from Trastuzumab, which can be monitored using selected reaction monitoring (SRM)[1]. | |||
T38907 |
FTISADTSK
|
||
FTISADTSK is an endogenous stable signature peptide derived from Trastuzumab, which can be accurately assessed using selected reaction monitoring (SRM). | |||
T15872 |
m-PEG4-Br
|
Others | Others |
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab. m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in v | |||
T16008 |
Maleimido-tri(ethylene glycol)-propionic acid
Mal-PEG3-acid |
Others | Others |
Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-spec | |||
T77885 |
(Aminooxy)acetamide-Val-Cit-PAB-MMAE
|
||
'(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) 是用于ADC药物-接头偶联物合成的中间体。该化合物通过与聚酰胺形成肟键,得到MMAE聚酰胺偶联物,进一步与Trastuzumab偶联,制备成ADC。' | |||
T36648 | Tucatinib hemiethanolate | ||
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 versus EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 relative to EGFR[1].Tucatinib blocks proliferation and the phosphorylation of HER2 and its downstream effector, Akt in HER2 overexpressing cell lines. In the ... |